EFFECTIVE AND BINDING AGREEMENT. Progenity and OIG agree as follows:
A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.
B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.
C. OIG may agree to a suspension of Progenity’s obligations under this CIA based on a certification by Progenity that it is no longer providing health care items or services that will be billed to any Federal health care program and it does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care program. If Progenity is relieved of its CIA obligations, Progenity shall be required to notify OIG in writing at least 30 days in advance if Progenity plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified.
D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Progenity’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.
E. The undersigned Progenity signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.
F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies or facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxx Xxxxxxx July 21, 2020 Xxxxxx Xxxxxxx DATE General Counsel, Progenity /s/ Xxxxxxxx X. Xxxxxxxx July 21, 2020 Xxxxxxxx X. Xxxxxxxx DATE X. Xxxxxxx Day Xxxxxx, Xxxx & Xxxxxxxx LLP Counsel for Progenity /s/ Xxxx X. Re July 20, 2020 XXXX X. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /s/ Xxxxx Xxxxxxx July 21, 2020 XXXXX XXXXXXX DATE Senior Counsel Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements ...
EFFECTIVE AND BINDING AGREEMENT. CRC and OIG agree as follows:
A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.
B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.
C. OIG may agree to a suspension of CRC’s obligations under this CIA based on a certification by CRC that it is no longer providing health care items or services that will be billed to any Federal health care program and it does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care program. If CRC is relieved of its CIA obligations,CRC shall be required to notify OIG in writing at least 30 days in advance if CRC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified.
D. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) CRC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.
E. The undersigned CRC signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.
F. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA.
EFFECTIVE AND BINDING AGREEMENT. DLDC and OIG agree as follows:
A. This IA shall become final and binding on the date the final signature is obtained on the IA.
B. This IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this IA.
C. OIG may agree to a suspension of DLDC’s obligations under this IA based on a certification by DLDC that it is no longer providing health care items or services that will be billed to any Federal health care program and it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If DLDC is relieved of its IA obligations, DLDC shall be required to notify OIG in writing at least 30 days in advance if DLDC plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the IA will be reactivated or modified.
D. All requirements and remedies set forth in this IA are in addition to and do not affect (1) DLDC’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.
E. The undersigned DLDC signatories represent and warrant that they are authorized to execute this IA. The undersigned OIG signatories represent that they are signing this IA in their official capacity and that they are authorized to execute this IA.
F. This IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same IA. Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this IA. ON BEHALF OF DIGESTIVE & LIVER DISEASE CONSULTANTS, P.A. /Xxxxxx Xxxxx/ 9/26/17 XXXXXX X. XXXXX, M.D. DATE Partner Digestive & Liver Disease Consultants, P.A. /Xxx Xxxxx/ 9/26/17 XXX XXXXX DATE Counsel for Digestive & Liver Disease Consultants, P.A /Xxxxxxxx Xxxxx Reddy/ 9/26/17 XXXXXXXX XXXXX REDDY DATE /Xxx Xxxxx/ _9/26/17 XXX XXXXX DATE Counsel for Xxxxxxxx Xxxxx Reddy /Xxxx X. Re/ 10/2/17 XXXX X. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /Xxxxx Xxxxxx/ 9/28/17 XXXXX X. XXXXXX DATE Senior Counsel Office of Inspec...
EFFECTIVE AND BINDING AGREEMENT. USPh, Old Towne, and OIG agree as follows:
A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.
B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.
C. OIG may agree to a suspension of USPh’s or Old Towne’s obligations under this CIA based on a certification by USPh or Old Towne that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If USPh or Old Towne is relieved of its CIA obligations, USPh or Old Towne will be required to notify OIG in writing at least 30 days in advance if USPh or Old Towne plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified.
D. The undersigned USPh and Old Towne signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.
E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.
EFFECTIVE AND BINDING AGREEMENT. GSK and OIG agree as follows:
A. This CIA shall be binding on the successors, assigns, and transferees of GSK;
B. This CIA shall become final and binding on the date the final signature is obtained on the CIA;
C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA; GlaxoSmithKline LLC Corporate Integrity Agreement
D. The undersigned GSK signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA.
E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. GlaxoSmithKline LLC Corporate Integrity Agreement This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.
EFFECTIVE AND BINDING AGREEMENT. Provider and OMIG agree as follows:
A. Good and valuable consideration has been exchanged between the parties to this CIA.
B. This CIA shall become final and binding on the date the final signature is obtained on the CIA as established in Section II. A.
C. This CIA shall be considered to include the Corporate Integrity Agreement and any Appendix, Attachment or Amendment to this CIA which is in writing and executed by the parties to this CIA. They shall collectively constitute the entire and complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA, or as may be otherwise permitted.
D. The terms of any Appendix, Attachment or Amendment to the CIA shall be incorporated by reference as if fully set forth in this CIA. If there is any conflict between a term in the CIA and any Appendix, Attachment or Amendment, the terms of the CIA shall control unless otherwise specifically stated in the terms of the Appendix, Attachment or Amendment.
E. This CIA shall be binding on the successors, assigns, and transferees of Provider.
F. All requirements and remedies set forth in this CIA are in addition to, and do not effect:
1. Provider’s responsibility to follow all applicable New York State and Federal health care program requirements or
2. the State of New York’s or the federal government’s right to impose appropriate remedies for failure to follow applicable program requirements.
G. The undersigned Provider signatories represent and warrant that they are authorized to execute this CIA. The undersigned OMIG signatory represents that he/she is signing this CIA in his/her official capacity and that he/she is authorized to execute this CIA.
H. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA.
EFFECTIVE AND BINDING AGREEMENT. A. All terms and conditions of the CIA not modified in this Amendment shall remain in effect for the remainder of the five-year period of compliance obligations that began on the CIA’s Effective Date of July 3, 2017. The Effective Date of this Amendment shall be the date the final signatory signs this Amendment (Amendment Effective Date).
B. The undersigned FHS and Xxxxx Xxxxxxxx signatories represent and warrant that they are authorized to execute this Amendment. The undersigned OIG signatories represent that they are signing this Amendment in their official capacities and that they are authorized to execute this Amendment.
C. This Amendment may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Amendment. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Amendment. /Xxxxxx Xxxxxx/ _ 2/19/20 XXXXXX XXXXXX DATE President Foundations Health Solutions, Inc. /Xxxx X. Xxxxxx/_ _ 2/19/20 XXXX X. XXXXXX DATE Counsel for Foundations Health Solutions, Inc. Xxxx Xxxxxxx Xxxxxx Xxxx LLP /Xxxxx Xxxxxxxx/_ _ 2/19/20 XXXXX XXXXXXXX DATE /Xxxx X. Xxxxxx/_ _ 2/19/20 XXXX X. XXXXXX DATE Counsel for Xxxxx Xxxxxxxx Xxxx Xxxxxxx Xxxxxx Xxxx LLP /Xxxx X. Re/ _ 2/28/2020 XXXX X. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /Xxxxx X. Xxxxx/ 3/2/2020 XXXXX X. XXXXX DATE Senior Counsel Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.
EFFECTIVE AND BINDING AGREEMENT. Biovail and OIG agree as follows:
A. This CIA shall be binding on the successors, assigns, and transferees of Biovail;
B. This CIA shall become final and binding on the date the final signature is obtained on the CIA;
C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA;
D. The undersigned Biovail signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA.
E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxxxx Xxxxxxx September 11, 2009 Xxxxxxxx Xxxxxxx DATE Vice President, Associate General Counsel Biovail Corporation /s/ Xxxxxxxx X. Xxxxxx 9/11/09 Xxxxxxxx X. Xxxxxx DATE Xxxxxxxxx & Xxxxxxx LLP Counsel for Biovail Corporation /s/ Xxxxxxx X. Xxxxxx 9/11/09 XXXXXXX X. XXXXXX DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.
EFFECTIVE AND BINDING AGREEMENT. Encore and OIG agree as follows:
A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.
B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.
EFFECTIVE AND BINDING AGREEMENT. Paksn and OIG agree as follows:
A. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.
B. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Paksn’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.
C. The undersigned Paksn signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.
D. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /Xxxxx Xxxxxxx/ 11/8/2023 Xxxxx Xxxxxxx DATE Owner /Xxxxx Xxxxx/ 11/8/2023 Xxxxx Xxxxx DATE Counsel for Paksn /Xxxxxxx Xxxxxx/ 11/8/23 Xxxxxxx Xxxxxx DATE Counsel for Paksn /Xxxx Re/ 2023.11.09 XXXX X. RE DATE Assistant Inspector General for Legal Affairs Office of Inspector General U. S. Department of Health and Human Services /Xxxxxxx Xxxxxxx/ 2023.11.09 Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.
